TRAW_OUT_1 [2025-04-02 18:45:14 -0400] 2109 Bytes | 618 tokens | Cum: 618 tkns (7.72% of 8k)
==========================================================================

Listen up, partner—it's 6:45:13 PM on Wed Apr 02, 2025 -0400, and I’m revved up about Traws Pharma (TRAW), climbing from 2.14 to 2.55. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Traws Pharma (TRAW)
IPO: IPO date unknown
Shares Outstanding: 5,030,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for Traws Pharma:

C1 - Apr-01-25 08:50PM - Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript
C2 - Mar-31-25 09:00AM - Traws Pharma Reports Full Year 2024 Results and Business Highlights
C3 - Mar-28-25 04:30PM - Traws Pharma Announces Management Updates
C4 - Mar-26-25 07:30AM - Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
C5 - Mar-25-25 07:30AM - Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR
C6 - Mar-24-25 07:00AM - Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
C7 - Mar-21-25 07:00AM - Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
C8 - Mar-03-25 07:00AM - Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Traws Pharma (TRAW)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

TRAW_OUT_3 [2025-04-02 18:45:19 -0400] 1113 Bytes | 341 tokens | Cum: 961 tkns (12.01% of 8k)
==========================================================================

Showing C2 (chunk 1 of 14): C2:
**Traws Pharma Reports Full Year 2024 Results and Business Highlights**
Date: Mar-31-25 09:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052342/0/en/Traws-Pharma-Reports-Full-Year-2024-Results-and-Business-Highlights.html

March 31, 2025 09:00 ET| Source:Traws Pharma, Inc.Traws Pharma, Inc.

Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data

Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the “Animal Rule”

Cash Runway to support planned operations into Q1 2026

Investor Update call today, March 31, 2025 at 10:00 AM ET

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” o

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TRAW_OUT_5 [2025-04-02 18:45:20 -0400] 910 Bytes | 270 tokens | Cum: 1360 tkns (17.00% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T18:32:19Z - Traws Pharma Reports Full Year 2024 Results and Business Highlights...
A2 - 2025-03-31T13:00:00Z - Traws Pharma Reports Full Year 2024 Results and Business Highlights - Traws Pharma (NASDAQ:TRAW)...
A3 - 2025-03-31T13:11:54Z - Traws Pharma Reports Full Year 2024 Results and Business Highlights...
A4 - 2025-03-31T13:12:03Z - Traws Pharma Reports Full Year 2024 Results and Business Highlights | Taiwan News | Mar. 31, 2025 21...
A5 - 2025-03-28T20:55:37Z - Traws Pharma Announces Management Updates...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

TRAW_OUT_7 [2025-04-02 18:45:24 -0400] 1099 Bytes | 314 tokens | Cum: 1676 tkns (20.95% of 8k)
==========================================================================

Showing A1 (chunk 1 of 14): A1:
**Traws Pharma Reports Full Year 2024 Results and Business Highlights**Date: 2025-03-31Source: {'uri': 'forextv.com', 'dataType': 'news', 'title': 'ForexTV'}URL: https://forextv.com/traws-pharma-reports-full-year-2024-results-and-business-highlights/Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data

Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the "Animal Rule"

Cash Runway to support planned operations into Q1 2026

Investor Update call today, March 31, 2025 at 10:00 AM ET

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TRAW_OUT_9 [2025-04-02 18:45:25 -0400] 701 Bytes | 215 tokens | Cum: 2007 tkns (25.09% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-05-16T13:29:00Z - Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
B2 - 2024-05-07T13:05:03Z - Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
B3 - 2024-05-07T12:00:00Z - Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
B4 - 2024-04-04T11:58:23Z - Why Flora Growth Shares Are Trading Lower By Around 20%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TRAW_OUT_11 [2025-04-02 18:45:26 -0400] 583 Bytes | 170 tokens | Cum: 2179 tkns (27.24% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/05/16/2883536/0/en/Traws-Pharma-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.htmlTraws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TRAW_OUT_13 [2025-04-02 18:45:27 -0400] 1096 Bytes | 280 tokens | Cum: 2491 tkns (31.14% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes and...

S2 - 2025-03-28 8-K Item 7.01 Regulation FD Disclosure.

On March 28, 2025, the Company issued a press release announcing the management changes discussed above. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

The information set forth under I...

S3 - 2025-03-10 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On March 10, 2025, Traws Pharma, Inc. (the Company) entered into an At The Market Offering Agrmt (the ATM Agrmt) with Citizens JMP Securities, LLC (Citizens), pursuant to which the Company may offer and sell shares o...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

TRAW_OUT_15 [2025-04-02 18:45:28 -0400] 1098 Bytes | 221 tokens | Cum: 2714 tkns (33.92% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should review the Risk Factors section of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following d

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

TRAW_OUT_17 [2025-04-02 18:45:37 -0400] 4428 Bytes | 1280 tokens | Cum: 3996 tkns (49.95% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 78,298 | Perf Month: -2.93% | Option/Short: No / Yes | Sales Y/Y TTM: 0.00% |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 103.72K | Perf Quarter: -72.45% | Short Float: 2.06% | ROE: -2255.45% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.75 | Index: - | Short Ratio: 0.74 | ROI: - |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 31.50 | Market Cap: 11.77M | Short Interest: 0.08M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.39 | Shs Outstand: 5.03M | Beta: 1.27 | EPS Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -12.67% | Shs Float: 3.70M | Sales Q/Q: 0.00% | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -48.56% | Inst Own: 11.22% | Sales past 5Y: -18.32% | Earnings: Mar 31 BMO |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -66.21% | Insider Own: 27.17% | Employees: 7 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: -8.30% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Traws Pharma, Inc. (TRAW) by CAUTREELS WERNER (Chief Executive Officer) on 2025-02-18
- Common Stock: 96348 shares at $0.01 (D)
- Pre-Funded Warrant (right to buy): 96348 shares at $0 (D)

No transactions recorded.

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 57000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -8475000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.32
Average Volume: 115369.13
30-Day High: 2.91
30-Day Low: 2.14

[Detailed Financials: Q3 2024]
- Total Assets: $8,936,000.0
- Total Liabilities: $10,969,000.0
- Total Equity: $-2,033,000.0
- Current Assets: $8,923,000.0
- Current Liabilities: $8,348,000.0

[Income Statement: Q3 2024]
- Revenue: $57,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -8.81

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-11,476,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $18,686,000.0
- Total Liabilities: $12,587,000.0
- Total Equity: $-105,520,000.0
- Current Assets: $18,671,000.0
- Current Liabilities: $9,910,000.0

[Income Statement: Q2 2024]
- Revenue: $57,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -4.87

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $496,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

TRAW_OUT_19 [2025-04-02 18:45:38 -0400] 676 Bytes | 167 tokens | Cum: 4412 tkns (55.15% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

TRAW_IN_21 [2025-04-02 18:45:38 -0400] 126 Bytes | 29 tokens | Cum: 4469 tkns (55.86% of 8k)
==========================================================================

====================================
[2025-04-02 18:45:38] # Analysis Completed
Elapsed Time: 25.33 seconds